Talazoparib

Talazoparib

Systematic (IUPAC) name
(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one
Clinical data
Legal status	Investigational
Identifiers
ChemSpider	28637772
UNII	9QHX048FRV
ChEMBL	CHEMBL3137320
Chemical data
Formula	C19H14F2N6O
Molar mass	380.35 g/mol
SMILES Cn1c(ncn1)[C@H]2c3c4c(cc(cc4N[C@@H]2c5ccc(cc5)F)F)c(=O)[nH]n3
InChI InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1 Key:HWGQMRYQVZSGDQ-HZPDHXFCSA-N

Talazoparib (BMN-673) is an investigational drug that acts as a PARP inhibitor. It is in clinical trials for various cancers.

Talazoparib is C₁₉H₁₄F₂N₆O.

Talazoparib tosylate is C₂₆H₂₂F₂N₆O₄S.^[1]

Approvals and indications

None yet.

Mechanism of action

Clinical trials

After trials for advanced hematological malignancies and for advanced or recurrent solid tumors.^[2] it is now in phase 3 for metastatic germline BRCA mutated breast cancer.^[3] Trial estimated to complete in June 2016.^[4]

As of January 2016 it in 14 active clinical trials.^[5]

References

1. Talazoparib tosylate
2. BioMarin Pharmaceutical Inc. (28 July 2011). "BioMarin Announces Second Quarter 2011 Financial Results". prnewswire.com.
3. "BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer". Benzinga.
4. A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
5. BMN 673 trials

External links

• Talazoparib. Chemspider.com structure etc